cladribine MS
Selected indexed studies
- Cladribine Tablets: A Review in Relapsing MS. (CNS Drugs, 2018) [PMID:30105527]
- Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. (Neurodegener Dis Manag, 2023) [PMID:36278394]
- High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. (CNS Drugs, 2022) [PMID:36350491]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. (2018) pubmed
- Cladribine Tablets: A Review in Relapsing MS. (2018) pubmed
- High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis. (2022) pubmed
- Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. (2023) pubmed
- Is therapy-free remission a realistic goal with cladribine tablets in multiple sclerosis? New insights into the mechanism of action and clinical implications of immune reconstitution with cladribine tablets in MS therapy. (2025) pubmed
- Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation. (2022) pubmed
- Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MS. (2025) pubmed
- Summary of Research: Blood Biomarker Dynamics in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study. (2025) pubmed
- Treatment-free remission in MS: long-term disease control with cladribine tablets. (2026) pubmed
- Identifying Cladribine prescription pattern in MS: an Italian multicentre study. (2025) pubmed